Business Context and Reporting Period
Matinas Biopharma Holdings, Inc., an emerging growth company, filed this Form 8-K on March 15, 2019. The filing reports the entry into a material definitive agreement for a public equity offering and provides preliminary financial position data as of December 31, 2018.
Key Financial Metrics
- Equity Offering: The Company entered into an underwriting agreement to sell 27,272,727 shares of common stock at $1.10 per share.
- Expected Proceeds: Net proceeds are expected to be approximately $27.8 million after underwriting discounts and offering expenses.
- Over-Allotment Option: The underwriter holds a 30-day option to purchase up to 4,090,909 additional shares.
- Cash Position: As of December 31, 2018, the Company held approximately $13.0 million in cash and cash equivalents (including restricted cash). This figure is preliminary, unaudited, and subject to change upon completion of the 2018 audit.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or margin figures for the reporting period.
Material Changes
The primary material change is the execution of the underwriting agreement with BTIG, LLC, significantly increasing the Company's expected liquidity upon closing. The filing notes that the preliminary prospectus supplement includes updated business and risk factors sections compared to prior filings.
Outlook, Risks, and Management Commentary
- Closing Timeline: The offering is expected to close on or about March 19, 2019, subject to customary conditions.
- Forward-Looking Statements: The Company cautions that statements regarding the anticipated closing and proceeds involve risks, including the ability to satisfy closing conditions in a timely manner.
- Financial Audit Status: The cash balance reported is unaudited; final figures may differ in the audited 2018 financial statements.
- Risk Factors: Updated risk factors are incorporated by reference in the filing (Exhibit 99.4).
Investor Verification Checklist
- Verify the final closing date of the offering and the actual net proceeds received.
- Confirm the final audited cash and cash equivalents balance for the year ended December 31, 2018.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Examine the updated Risk Factors section (Exhibit 99.4) for new disclosures regarding the Company's operations and capital structure.
- Monitor whether the underwriter exercises the 30-day over-allotment option.